The Maudsley Prescribing Guidelines Series-The Maudsley Deprescribing Guidelines Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs
Samenvatting
Comprehensive resource describing guidelines for safely reducing or stopping (deprescribing) antidepressants, benzodiazepines, gabapentinoids and z-drugs for patients, including step-by-step guidance for all commonly used medications, covering common pitfalls, troubleshooting, supportive strategies, and more.
Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so.
The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment.
This evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts).
Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors’ work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as:
- Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs
- Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process
- Distinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat
- The difference between physical dependence and addiction/substance use disorder
- Explanation of why and how to implement hyperbolic tapering in clinical practice
- Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches
- Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual
- Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse.
Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine.
The Maudsley® Deprescribing Guidelines
Comprehensive resource describing guidelines for safely reducing or stopping (deprescribing) antidepressants, benzodiazepines, gabapentinoids and z-drugs for patients, including step-by-step guidance for all commonly used medications, covering common pitfalls, troubleshooting, supportive strategies, and more.
Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so.
The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment.
This evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts).
Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors’ work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as:
- Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs
- Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process
- Distinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat
- The difference between physical dependence and addiction/substance use disorder
- Explanation of why and how to implement hyperbolic tapering in clinical practice
- Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches
- Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual
- Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse.
Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine.
Productspecificaties
Inhoud
- Taal
- en
- Uitvoering
- Paperback
- Oorspronkelijke releasedatum
- 15 februari 2024
- Aantal pagina's
- 592
Betrokkenen
- Hoofdauteur
- Tweede Auteur
- Hoofduitgeverij
Informatie over de fabrikant
- Fabrikant Naam
- Wiley-vch Gmbh
- Fabrikant Adres
- Boschstrasse 12 - Weinheim
- E-mailadres of online contactformulier van de fabrikant
- product_safety@wiley.com
Overige kenmerken
- Product breedte
- 168 mm
- Product hoogte
- 31 mm
- Product lengte
- 241 mm
- Studieboek
- Nee
- Verpakking breedte
- 165 mm
- Verpakking hoogte
- 38 mm
- Verpakking lengte
- 242 mm
- Verpakkingsgewicht
- 1127 g
EAN
- EAN
- 9781119822981
Productveiligheid
De verantwoordelijk marktdeelnemer in de EU zorgt voor het nakomen van verplichtingen op het gebied van productveiligheid.
Je vindt dit artikel in
Documenten
Reviews
Inhoudelijk prima boek over afbouwen. Maar. Nu ik het boek van A tot Z lees kom ik er achter dat er een heel hoofdstuk ontbreekt! vanaf p 480 is er niets meer, terwijl het boek 553 pagina's zou moeten hebben. Een produktie fout dus. Hebben anderen dit ook? Wie kan ik het ontbrekend hoofdstuk vragen?
Kies gewenste uitvoering
Prijs inclusief verzendkosten, verstuurd door bol
Ophalen bij een bol afhaalpunt mogelijk
30 dagen bedenktijd en gratis retourneren via mijn bol
Dag en nacht klantenservice
Doordeweeks ook ’s avonds in huis



















